SEC Form 4 · accession 0000899243-16-012448
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth T. Mills
Officer — President and CEO · Director
Period of report
Jan 28, 2016
Accepted (ET)
Feb 1, 2016 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.09 | Jan 28, 2016 | A | 225,000 | A | — | Jan 27, 2026 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/28/2017 while the optionee provides continuous service to the Issuer.